<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876733</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1524</org_study_id>
    <nct_id>NCT00876733</nct_id>
  </id_info>
  <brief_title>Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients</brief_title>
  <official_title>Non-Interventional Observational Study With Viramune Plus ARV in HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This observational study is supposed to assess (under conditions of clinical practice in
      daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g.
      Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir and Lamivudine) or Truvada (tenofovir
      and emtricitabine) will durably suppress viral load below the limit of detection or will
      maintain suppression of viral replication (HIV-RNA below limit of detection) achieved under
      previous anti-retroviral combination therapy after switch to combination treatment of
      Viramune (nevirapine) and ARV, e.g. Combivir (Zidovudine and Lamivudine), Kivexa (Abacavir
      and Lamivudine) or Truvada (tenofovir and emtricitabine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with Treatment Emergent Adverse Events (AE) and All Serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Viral Load After 12 Months From Baseline.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The change in the log10 viral load from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a negative change represents a decrease in viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Viral Load After 36 Months From Baseline.</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Cluster of Differentiation 4 (CD4+) Cell Count After 12 Months From Baseline.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The change in the CD4+ cell count from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the CD4+ Cell Count After 36 Months From Baseline.</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The change in the CD4+ cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Total Cholesterol) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Total Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (HDL Cholesterol) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (LDL Cholesterol) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Triglycerides) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Triglycerides) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Blood Glucose) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Blood Glucose) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (ALT) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (AST) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Gamma GT) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Creatinine) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Creatinine) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Haemoglobin) After 12 Months From Baseline</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The changes in the laboratory data (Haemoglobin) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (ALT) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (AST) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Gamma GT) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</measure>
    <time_frame>Baseline and 36 months</time_frame>
    <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">605</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV treatment</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  male and female

          -  18 years or older

          -  written informed consent

          -  The inclusion criteria for treatment with Viramune plus other antiretroviral
             combination drugs are to be based on the current information for healthcare
             professionals / SmPC

        Exclusion criteria:

          -  Pregnant patients

          -  The exclusion criteria for the treatment of Viramune plus other antiretroviral
             combination drugs are to be based on the current SmPC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 14</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 12</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 13</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 15</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 19</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 21</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 23</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 24</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 28</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 30</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 31</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 34</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 38</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 41</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 54</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 60</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 63</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 8</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 58</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 50</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 48</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 27</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 49</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 62</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 9</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 32</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 59</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 65</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 57</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 56</name>
      <address>
        <city>Fürth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 29</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 33</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 42</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 47</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 51</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 40</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 43</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 46</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 6</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 25</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 37</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 53</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 61</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 11</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 52</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 18</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 20</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 22</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 26</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 35</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 16</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 17</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 39</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 55</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 10</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 36</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 64</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 7</name>
      <address>
        <city>Pforzheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 66</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 45</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 44</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <results_first_submitted>December 27, 2014</results_first_submitted>
  <results_first_submitted_qc>January 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <last_update_submitted>January 14, 2015</last_update_submitted>
  <last_update_submitted_qc>January 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment-naive Patients</title>
          <description>Patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="P2">
          <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="P3">
          <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="P4">
          <title>Patients With Baseline Viral Load Not Documented</title>
          <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="197"/>
                <participants group_id="P2" count="161"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data not available</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This patient set includes all HIV-1 infected patients who were dispensed Viramune® and were documented to have taken at least one dose of Viramune®and of a antiretroviral combination partner.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment-naive Patients</title>
          <description>Patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="B2">
          <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="B3">
          <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="B4">
          <title>Patients With Baseline Viral Load Not Documented</title>
          <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="288"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="21"/>
            <count group_id="B5" value="605"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" spread="9.9"/>
                    <measurement group_id="B2" value="43.8" spread="9.6"/>
                    <measurement group_id="B3" value="40.9" spread="9.4"/>
                    <measurement group_id="B4" value="43.6" spread="7.8"/>
                    <measurement group_id="B5" value="41.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs</title>
        <description>Number of participants with Treatment Emergent Adverse Events (AE) and All Serious AEs</description>
        <time_frame>36 months</time_frame>
        <population>Patients from Full Analysis Set (FAS): This patient set includes all patients in the treated set who have analysable data in at least one efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs</title>
          <description>Number of participants with Treatment Emergent Adverse Events (AE) and All Serious AEs</description>
          <population>Patients from Full Analysis Set (FAS): This patient set includes all patients in the treated set who have analysable data in at least one efficacy endpoint.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Viral Load After 12 Months From Baseline.</title>
        <description>The change in the log10 viral load from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a negative change represents a decrease in viral load.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from FAS with values for viral load at baseline and after 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Viral Load After 12 Months From Baseline.</title>
          <description>The change in the log10 viral load from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a negative change represents a decrease in viral load.</description>
          <population>Patients from FAS with values for viral load at baseline and after 12 months.</population>
          <units>Log10 copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.8"/>
                    <measurement group_id="O3" value="-1.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Viral Load After 36 Months From Baseline.</title>
        <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from FAS with values for viral load at baseline and after 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Viral Load After 36 Months From Baseline.</title>
          <description>The change in the log10 viral load from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a negative change represents a decrease in viral load.</description>
          <population>Patients from FAS with values for viral load at baseline and after 36 months.</population>
          <units>Log10 copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.4"/>
                    <measurement group_id="O2" value="-0.2" spread="1.1"/>
                    <measurement group_id="O3" value="-2.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Cluster of Differentiation 4 (CD4+) Cell Count After 12 Months From Baseline.</title>
        <description>The change in the CD4+ cell count from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from FAS with values for CD4+ at baseline and after 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Cluster of Differentiation 4 (CD4+) Cell Count After 12 Months From Baseline.</title>
          <description>The change in the CD4+ cell count from baseline after 12 months was calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
          <population>Patients from FAS with values for CD4+ at baseline and after 12 months.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.7" spread="165.0"/>
                    <measurement group_id="O2" value="54.6" spread="145.3"/>
                    <measurement group_id="O3" value="82.8" spread="269.5"/>
                    <measurement group_id="O4" value="128.0" spread="223.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the CD4+ Cell Count After 36 Months From Baseline.</title>
        <description>The change in the CD4+ cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from FAS with values for CD4+ at baseline and after 36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the CD4+ Cell Count After 36 Months From Baseline.</title>
          <description>The change in the CD4+ cell count from baseline after 36 months was calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase in CD4+ cell count.</description>
          <population>Patients from FAS with values for CD4+ at baseline and after 36 months.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="181"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.7" spread="200.4"/>
                    <measurement group_id="O2" value="2.8" spread="221.3"/>
                    <measurement group_id="O3" value="116.0" spread="317.7"/>
                    <measurement group_id="O4" value="63.5" spread="152.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Total Cholesterol) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Total Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Total Cholesterol at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Total Cholesterol) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Total Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Total Cholesterol at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="36.2"/>
                    <measurement group_id="O2" value="-3.0" spread="43.2"/>
                    <measurement group_id="O3" value="15.8" spread="32.8"/>
                    <measurement group_id="O4" value="16.4" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (HDL Cholesterol) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for HDL Cholesterol at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (HDL Cholesterol) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for HDL Cholesterol at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="14.3"/>
                    <measurement group_id="O2" value="4.2" spread="15.0"/>
                    <measurement group_id="O3" value="10.9" spread="14.9"/>
                    <measurement group_id="O4" value="-13.2" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (LDL Cholesterol) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for LDL Cholesterol at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (LDL Cholesterol) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for LDL Cholesterol at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="29.6"/>
                    <measurement group_id="O2" value="2.4" spread="35.7"/>
                    <measurement group_id="O3" value="14.4" spread="30.5"/>
                    <measurement group_id="O4" value="13.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Triglycerides) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Triglycerides) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Triglycerides at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Triglycerides) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Triglycerides) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Triglycerides at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="106.7"/>
                    <measurement group_id="O2" value="-61.6" spread="180.2"/>
                    <measurement group_id="O3" value="-24.0" spread="78.9"/>
                    <measurement group_id="O4" value="16.3" spread="47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Blood Glucose) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Blood Glucose) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Blood Glucose at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Blood Glucose) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Blood Glucose) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Blood Glucose at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="20.6"/>
                    <measurement group_id="O2" value="-3.6" spread="16.9"/>
                    <measurement group_id="O3" value="0.3" spread="24.9"/>
                    <measurement group_id="O4" value="-8.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (ALT) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for ALT at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (ALT) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for ALT at baseline and at month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="20.5"/>
                    <measurement group_id="O2" value="10.2" spread="28.8"/>
                    <measurement group_id="O3" value="7.0" spread="28.4"/>
                    <measurement group_id="O4" value="9.7" spread="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (AST) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for AST at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (AST) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for AST at baseline and at month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="19.1"/>
                    <measurement group_id="O2" value="4.4" spread="24.7"/>
                    <measurement group_id="O3" value="3.0" spread="20.9"/>
                    <measurement group_id="O4" value="8.3" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Gamma GT) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Gamma GT) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 12.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="72.4"/>
                    <measurement group_id="O2" value="25.4" spread="57.7"/>
                    <measurement group_id="O3" value="23.7" spread="62.3"/>
                    <measurement group_id="O4" value="9.1" spread="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Creatinine) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Creatinine) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Creatinine at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Creatinine) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Creatinine) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Creatinine at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                    <measurement group_id="O4" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Haemoglobin) After 12 Months From Baseline</title>
        <description>The changes in the laboratory data (Haemoglobin) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Patients from TS with evaluable data for Haemoglobin at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Haemoglobin) After 12 Months From Baseline</title>
          <description>The changes in the laboratory data (Haemoglobin) from baseline after 12 months were calculated by subtracting the baseline value from the value after 12 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Haemoglobin at baseline and at month 12.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.1"/>
                    <measurement group_id="O2" value="0.3" spread="1.2"/>
                    <measurement group_id="O3" value="0.3" spread="0.9"/>
                    <measurement group_id="O4" value="0.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Total Cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Total Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Total Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Total Cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="39.0"/>
                    <measurement group_id="O2" value="2.0" spread="44.4"/>
                    <measurement group_id="O3" value="24.2" spread="42.4"/>
                    <measurement group_id="O4" value="41.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for HDL Cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (HDL Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data ( High density protein (HDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for HDL Cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" spread="21.4"/>
                    <measurement group_id="O2" value="4.4" spread="20.7"/>
                    <measurement group_id="O3" value="11.1" spread="11.9"/>
                    <measurement group_id="O4" value="-19.6" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for LDL Cholesterol at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (LDL Cholesterol) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data ( Low density protein (LDL) Cholesterol) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for LDL Cholesterol at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="25.8"/>
                    <measurement group_id="O2" value="15.8" spread="38.1"/>
                    <measurement group_id="O3" value="23.8" spread="44.7"/>
                    <measurement group_id="O4" value="22.7" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Triglycerides at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Triglycerides) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Triglycerides) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Triglycerides at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="91.3"/>
                    <measurement group_id="O2" value="-73.7" spread="252.6"/>
                    <measurement group_id="O3" value="-17.2" spread="98.0"/>
                    <measurement group_id="O4" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Blood Glucose at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Blood Glucose) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Blood Glucose) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Blood Glucose at baseline and at month 36.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="27.2"/>
                    <measurement group_id="O2" value="0.0" spread="19.9"/>
                    <measurement group_id="O3" value="0.7" spread="36.4"/>
                    <measurement group_id="O4" value="-7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (ALT) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for ALT at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (ALT) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Alanine transaminase (ALT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for ALT at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="107.1"/>
                    <measurement group_id="O2" value="4.0" spread="33.7"/>
                    <measurement group_id="O3" value="11.8" spread="27.7"/>
                    <measurement group_id="O4" value="5.2" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (AST) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for AST at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (AST) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Aspartate transminase (AST)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for AST at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="75.3"/>
                    <measurement group_id="O2" value="0.1" spread="24.6"/>
                    <measurement group_id="O3" value="5.5" spread="27.1"/>
                    <measurement group_id="O4" value="-2.7" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Gamma GT) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Gamma GT) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Gamma glutamyl transferase (Gamma GT)) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Gamma GT at baseline and at month 36.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="102.5"/>
                    <measurement group_id="O2" value="45.0" spread="112.6"/>
                    <measurement group_id="O3" value="50.3" spread="50.3"/>
                    <measurement group_id="O4" value="12.9" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Creatinine at baseline and at month 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Creatinine) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Creatinine) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Creatinine at baseline and at month 12.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                    <measurement group_id="O4" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</title>
        <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
        <time_frame>Baseline and 36 months</time_frame>
        <population>Patients from TS with evaluable data for Haemoglobin at baseline and at month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment-naive Patients</title>
            <description>Patients who were not pretreated with HIV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
            <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
          </group>
          <group group_id="O3">
            <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
            <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
          </group>
          <group group_id="O4">
            <title>Patients With Baseline Viral Load Not Documented</title>
            <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Laboratory Data (Haemoglobin) After 36 Months From Baseline</title>
          <description>The changes in the laboratory data (Haemoglobin) from baseline after 36 months were calculated by subtracting the baseline value from the value after 36 months. Therefore, a positive change represents an increase, a negative change represents a decrease in the data.</description>
          <population>Patients from TS with evaluable data for Haemoglobin at baseline and at month 36.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="0.2" spread="1.2"/>
                    <measurement group_id="O3" value="0.5" spread="1.4"/>
                    <measurement group_id="O4" value="-0.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment-naive Patients</title>
          <description>Patients who were not pretreated with HIV therapy.</description>
        </group>
        <group group_id="E2">
          <title>Pretreated Patients, Baseline Viral Load ≤ 50 Copies/mL</title>
          <description>Patients switching from a virologically effective treatment regimen (i.e. due to intolerance), with a viral load ≤ 50 copies/mL.</description>
        </group>
        <group group_id="E3">
          <title>Pretreated Patients, Baseline Viral Load &gt; 50 Copies/mL</title>
          <description>Patients switching from a virologically ineffective treatment regimen, viral load &gt;50 copies/mL.</description>
        </group>
        <group group_id="E4">
          <title>Patients With Baseline Viral Load Not Documented</title>
          <description>Patients who could not be assigned to one of the three subgroups and had no documented viral load value.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bursa removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Laparoscopic surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Laser therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

